PHVS Quote, Financials, Valuation and Earnings

NewAmsterdam Pharma Co. NV has a net margin of -- compared to Pharvaris NV's net margin of -234134.38%. Pharvaris NV's return on equity of -63% beat NewAmsterdam Pharma Co. NV's return on equity of -27.36%.

Pharvaris NV has a consensus price target of $46.30, signalling upside risk potential of 65.34%. On the other hand NewAmsterdam Pharma Co. NV has an analysts' consensus of $48.95 which suggests that it could grow by 42.81%. Given that Pharvaris NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe Pharvaris NV is more attractive than NewAmsterdam Pharma Co. NV.

Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NewAmsterdam Pharma Co. NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NewAmsterdam Pharma Co. NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. NewAmsterdam Pharma Co. NV pays out -- of its earnings as a dividend.

Pharvaris NV quarterly revenues are --, which are smaller than NewAmsterdam Pharma Co. NV quarterly revenues of $32K. Pharvaris NV's net income of -$43.4M is higher than NewAmsterdam Pharma Co. NV's net income of -$74.9M. Notably, Pharvaris NV's price-to-earnings ratio is -- while NewAmsterdam Pharma Co. NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 178.26x for NewAmsterdam Pharma Co. NV. Usually stocks with elevated PS ratios are considered overvalued.

Pharming Group NV has a net margin of -- compared to Pharvaris NV's net margin of 7.71%. Pharvaris NV's return on equity of -63% beat Pharming Group NV's return on equity of 0.39%.

Pharvaris NV has a consensus price target of $46.30, signalling upside risk potential of 65.34%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 89.37%. Given that Pharming Group NV has higher upside potential than Pharvaris NV, analysts believe Pharming Group NV is more attractive than Pharvaris NV.

Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group NV has a beta of -0.009, suggesting its less volatile than the S&P 500 by 100.89%.

Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.

Pharvaris NV quarterly revenues are --, which are smaller than Pharming Group NV quarterly revenues of $96.9M. Pharvaris NV's net income of -$43.4M is lower than Pharming Group NV's net income of $7.5M. Notably, Pharvaris NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,144.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 3.08x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.

ProQR Therapeutics NV has a net margin of -- compared to Pharvaris NV's net margin of -381.88%. Pharvaris NV's return on equity of -63% beat ProQR Therapeutics NV's return on equity of -67.34%.

Pharvaris NV has a consensus price target of $46.30, signalling upside risk potential of 65.34%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 458.18%. Given that ProQR Therapeutics NV has higher upside potential than Pharvaris NV, analysts believe ProQR Therapeutics NV is more attractive than Pharvaris NV.

Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.200, suggesting its less volatile than the S&P 500 by 79.991%.

Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.

Pharvaris NV quarterly revenues are --, which are smaller than ProQR Therapeutics NV quarterly revenues of $3.4M. Pharvaris NV's net income of -$43.4M is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, Pharvaris NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 9.62x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.

uniQure NV has a net margin of -- compared to Pharvaris NV's net margin of -2175.87%. Pharvaris NV's return on equity of -63% beat uniQure NV's return on equity of -382.35%.

Pharvaris NV has a consensus price target of $46.30, signalling upside risk potential of 65.34%. On the other hand uniQure NV has an analysts' consensus of $53.52 which suggests that it could grow by 212.7%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.

Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.669%.

Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

Pharvaris NV quarterly revenues are --, which are smaller than uniQure NV quarterly revenues of $3.7M. Pharvaris NV's net income of -$43.4M is higher than uniQure NV's net income of -$80.5M. Notably, Pharvaris NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 58.48x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.